Press Release Details

Cerus Receives Discover Magazine Innovation Award

June, 12 2001
Cerus Corporation (Nasdaq: CERS) today announced that the company's Helinx technology received the Discover Magazine Innovation Award. Each year, Discover magazine honors forward-looking, meaningful technologies that will potentially impact society in a significant way. Helinx technology represents a revolutionary approach to improving the safety of blood transfusions and also offers potential therapeutic applications. Laurence Corash, M.D., chief medical officer of Cerus, accepted the Discover Award on behalf of Cerus at ceremonies in New York City on June 12, 2001.

"It is a tremendous honor to have our Helinx technology recognized as a top innovation by a respected publication like Discover," said Dr. Corash. "We believe Helinx has broad potential for many medical systems and therapeutics and we're looking forward to commercializing its first application, the INTERCEPT Blood Systems, in collaboration with Baxter Healthcare Corporation. We believe these systems will significantly improve the safety of the world's blood supply."

Helinx technology inactivates disease-causing agents by targeting and locking their nucleic acids (DNA or RNA). This technology has the ability to prevent the replication of viruses, bacteria and other pathogens and to control cellular proliferation. The first applications of Helinx are with the INTERCEPT Blood Systems. The systems, being jointly developed by Cerus and Baxter Healthcare, are designed to inactivate viruses, bacteria, and other pathogens in donated blood components used for transfusions. Applications of Helinx also are being developed in the areas of leukemia, sickle cell anemia, heart disease, and in cellular vaccines.

"We are honored to have received the Discover Award for our Helinx technology," said Stephen T. Isaacs, president and chief executive officer of Cerus. "With the INTERCEPT Platelet System nearing regulatory approval in Europe and the completion of our United States Phase III clinical trial, this prestigious award further validates many years of hard work and scientific discovery by Cerus researchers."


Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx™ technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.


The Discover Magazine Innovation Awards were created in 1990, to honor and recognize the innovations that are shaping our lives. Each year, Discover's editorial staff reaches out to hundreds of eminent scientists in a wide range of fields to solicit the best and the brightest nominees. The editorial staff selects a number of candidates for each category. Information on each candidate is then sent on to an independent panel of experts, which selects the finalists. Discover editors choose the winners in each of the key areas of technology. Previous winners have included Boeing, Microsoft, IBM, Toyota, and various researchers from NASA and MIT. In 1996, the Christopher Columbus Fellowship Foundation instituted the $100,000 Christopher Columbus Foundation Award and began sponsoring the Discover Awards ceremony.

Helinx is a trademark of Cerus Corporation

Intercept Blood System, Intercept Platelet System, Intercept Plasma System and Intercept Red Blood Cell System are trademarks of Baxter International, Inc. (NYSE: BAX)

Statements in this news release regarding product development and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, market acceptance of any products, competitive conditions, corporate partnerships and other factors discussed in the companyÕs most recent Report on Form 10-Q.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600